Bio-Techne's Stock: Stabilizing Markets & Optimistic Outlook

Bio-Techne Corporation, based in Minneapolis, specializes in life science products and services, with a market value of nine point six billion dollars. Despite a significant stock decline of nearly twenty percent over the past year, the company has shown resilience in the US academic market and strong demand from large pharmaceutical customers. Bio-Technes first-quarter results showed a one percent decrease in organic sales and flat adjusted earnings per share, meeting analyst expectations. Analysts forecast an adjusted earnings per share of one dollar and sixty-six cents for the full fiscal year two thousand twenty-six. With a Strong Buy consensus rating and a raised price target by Wells Fargo analyst Brandon Couillard, investors may see potential upside.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.